Reported 2 days ago
AbbVie Inc. has received FDA approval to expand the use of Mavyret, its oral antiviral drug for treating Hepatitis C, for both adults and children aged three and older. The updated label allows Mavyret to be used for patients without cirrhosis or with compensated cirrhosis, enabling treatment completion in eight weeks. This decision stems from encouraging Phase 3 study results demonstrating the drug's safety and effectiveness for acute Hepatitis C cases.
Source: YAHOO